Search results for "LDL"

showing 10 items of 664 documents

Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.

2009

Abstract Objective : Subjects with rheumatoid arthritis (RA) have increased cardiovascular risk and may show atherogenic forms of dyslipidemia. The present study investigated whether patients with early RA, beyond alterations in plasma lipids, also show lower LDL size and altered LDL subclass distribution. Design and Methods We identified 25 subjects with RA (47±8 years, body mass index (BMI) 25±4kg/m 2 ) by the American College of Rheumatology diagnostic criteria, with a disease durations Results As compared to controls RA patients had higher plasma triglycerides (1.8±0.5 vs. 1.0±0.5mmol/L, p p =0.0027), while total- and LDL-cholesterol concentrations were similar. LDL particle size was lo…

medicine.medical_specialtyCholesterolbusiness.industry10265 Clinic for Endocrinology and DiabetologyArthritisBlood lipids610 Medicine & healthRheumatoid arthritis small dense LDL HDL-cholesterol Triglyceridesmedicine.disease2705 Cardiology and Cardiovascular MedicineRheumatologychemistry.chemical_compoundHigh-density lipoproteinEndocrinologychemistryInternal medicineRheumatoid arthritisLow-density lipoproteinmedicineCardiology and Cardiovascular MedicinebusinessaterosclerosiDyslipidemia
researchProduct

Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management

2013

Abstract Introduction and objectives Although atherogenic dyslipidemia is a recognized cardiovascular risk factor, it is often underassessed and thus undertreated and poorly controlled in clinical practice. The objective of this study was to reach a multidisciplinary consensus for the establishment of a set of clinical recommendations on atherogenic dyslipidemia to optimize its prevention, early detection, diagnostic evaluation, therapeutic approach, and follow-up. Methods After a review of the scientific evidence, a scientific committee formulated 87 recommendations related to atherogenic dyslipidemia, which were grouped into 5 subject areas: general concepts (10 items), impact and epidemi…

medicine.medical_specialtyConsensusDelphi TechniqueGuidelines as TopicScientific evidenceTherapeutic approachRisk FactorsMultidisciplinary approachEpidemiologymedicineHumansRisk factorDyslipidemiascomputer.programming_languageAtherogenic dyslipidemiaEvidence-Based Medicinebusiness.industryExpert consensusGeneral MedicineAtherosclerosisAtherogenic dyslipidemia Cardiovascular risk Consenso Consensus Delphi Dislipemia aterogénica HDL-C LDL-C Riesgo cardiovascular high-density lipoprotein cholesterol low-density lipoprotein cholesterolCardiovascular DiseasesFamily medicinePhysical therapybusinesscomputerDelphiRevista Española de Cardiología (English Edition)
researchProduct

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk

2015

Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.

medicine.medical_specialtyConsensusStatinEpidemiologymedicine.drug_classHypercholesterolemia610 Medicine & healthComorbidity030204 cardiovascular system & hematologyRisk Assessment2705 Cardiology and Cardiovascular MedicinePatient care03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk Factors540 ChemistrymedicineHumans030212 general & internal medicineIntensive care medicine10038 Institute of Clinical Chemistrybusiness.industryCholesterolTreat to targetCholesterol LDLGuidelineStatin treatmentTreatment OutcomechemistryCardiovascular DiseasesPractice Guidelines as TopicPhysical therapyLDL Cholesterol Lipoproteinslipids (amino acids peptides and proteins)Disease preventionHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkers2713 EpidemiologyEuropean Journal of Preventive Cardiology
researchProduct

Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea.

2012

Patients with obstructive sleep apnea (OSA) have proatherogenic dyslipidemia. We analyzed predictors of low-density lipoproteins' (LDLs) size in patients with OSA. In a cross-sectional study including 58 participants with OSA (30 without the metabolic syndrome [MetS] and 28 with MetS), we evaluated the size of LDL by gradient gel electrophoresis. Compared with patients without the MetS, those with MetS showed lower LDL size ( P = .007), due to a reduction in large LDL-I particles ( P = .002) and an increase in small, dense LDL-IIIA ( P = .048) and LDL-IIIB ( P = .037). The size of LDL correlated inversely with age ( r = −.268, P = .042) and serum triglycerides ( r = −.364, P = .005), and p…

medicine.medical_specialtyCross-sectional studyPolysomnography10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPolysomnography2705 Cardiology and Cardiovascular MedicineInternal medicinemedicineLow densityobstructive sleep apnea metabolic syndrome low-density lipoprotein size small dense low-density lipoprotein atherosclerosisHumansIn patientDyslipidemiasMetabolic SyndromeSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industrySleep apneamedicine.diseaseLipoproteins LDLObstructive sleep apneaCross-Sectional StudiesEndocrinologyLinear Modelslipids (amino acids peptides and proteins)Metabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemia
researchProduct

Modeling the epidemiological history of plague in Central Asia: Palaeoclimatic forcing on a disease system over the past millennium

2010

Abstract Background Human cases of plague (Yersinia pestis) infection originate, ultimately, in the bacterium's wildlife host populations. The epidemiological dynamics of the wildlife reservoir therefore determine the abundance, distribution and evolution of the pathogen, which in turn shape the frequency, distribution and virulence of human cases. Earlier studies have shown clear evidence of climatic forcing on contemporary plague abundance in rodents and humans. Results We find that high-resolution palaeoclimatic indices correlate with plague prevalence and population density in a major plague host species, the great gerbil (Rhombomys opimus), over 1949-1995. Climate-driven models trained…

medicine.medical_specialtyDisease reservoir010504 meteorology & atmospheric sciencesYersinia pestisPhysiologyasie centrale[SDV]Life Sciences [q-bio]WildlifePlant ScienceDiseasePlague (disease)01 natural sciencesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesStructural BiologyEpidemiologymedicineréchauffement climatiqueBiologylcsh:QH301-705.5Ecology Evolution Behavior and Systematics030304 developmental biology0105 earth and related environmental sciences0303 health sciencesrongeurRhombomys opimusbiologyAgricultural and Biological Sciences(all)EcologyBiochemistry Genetics and Molecular Biology(all)Global warmingCell Biologybiology.organism_classificationlcsh:Biology (General)Yersinia pestis13. Climate actionGeneral Agricultural and Biological SciencesDevelopmental BiologyBiotechnology
researchProduct

Effect of β-cryptoxanthin plus phytosterols on cardiovascular risk and bone turnover markers in post-menopausal women: a randomized crossover trial.

2014

Abstract Background and aim Post-menopausal women are at higher risk of cardiovascular disease and bone demineralization. Phytosterols (PS) may be used for hypercholesterolemia in some groups and β-cryptoxanthin (β-Cx) displays a unique anabolic effect on bone. Our aim was to assess the changes in cardiovascular and bone turnover markers from the oral intake of β-Cx and PS in post-menopausal women. Methods and results A randomized, double-blind, crossover study with β-Cx (0.75 mg/day) and PS (1.5 g/day), single and combined, was performed in 38 postmenopausal women. Diet was supplemented with 1 × 250 mL milk-based fruit drink/day for 4 weeks with a wash-out period of 4-weeks in between. Ser…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismCampesterolOsteoporosisHypercholesterolemiaMedicine (miscellaneous)Parathyroid hormoneAdministration OralGastroenterologyBone and BonesBone remodelingchemistry.chemical_compoundDouble-Blind MethodRisk FactorsInternal medicineStatistical significancemedicineHumansCryptoxanthinsTriglyceridesAgedNutrition and DieteticsCross-Over StudiesDose-Response Relationship Drugbusiness.industryCholesterol HDLPhytosterolsCholesterol LDLMiddle Agedmedicine.diseaseCrossover studySitosterolsHealthy VolunteersClinical trialPostmenopauseEndocrinologyCholesterolTreatment OutcomechemistrySelective estrogen receptor modulatorCardiovascular DiseasesDietary SupplementsFemaleCardiology and Cardiovascular MedicinebusinessNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies

2019

Background: Age, smoking, hypercholesterolemia, and hypertension are major risk factors for atherosclerotic cardiovascular disease. Objective: We examined whether the effects of alirocumab on low-density lipoprotein cholesterol (LDL-C) differed according to age, hypertension, or smoking status. Methods: Data were pooled from 10 Phase 3 ODYSSEY randomized trials (24–104 weeks’ duration) in 4983 people with heterozygous familial hypercholesterolemia (FH) or non–familial hypercholesterolemia (3188 on alirocumab, 1795 on control [620 on ezetimibe and 1175 on placebo]). Most participants received concomitant maximum tolerated statin therapy. In 8 trials, the alirocumab dose was increased from 75…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedPlacebolaw.inventionPCSK903 medical and health sciencesAge0302 clinical medicineRandomized controlled trialEzetimibeRisk FactorslawInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineAdverse effectAgedAlirocumabNutrition and Dieteticsbusiness.industryPCSK9SmokingAge FactorsCholesterol LDLMiddle Agedmedicine.diseaseCholesterolTreatment OutcomeConcomitantHypertensionCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of Clinical Lipidology
researchProduct

Small, dense low-density-lipoproteins and the metabolic syndrome.

2006

Small, dense low-density-lipoproteins (LDL) are associated with increased risk for cardiovascular diseases and diabetes mellitus and a reduction in LDL size has been reported in patients with coronary and non-coronary forms of atherosclerosis. LDL size has been accepted as an important predictor of cardiovascular events and progression of coronary artery disease as well as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. Small, dense LDL, with elevated triglyceride levels and low HDL-cholesterol concentrations, constitute the 'atherogenic lipoprotein phenotype (ALP)', a form of atherogenic dyslipidemia that is a feature of type …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismMyocardial InfarctionCoronary DiseaseType 2 diabetesmetabolic syndromeCoronary artery diseasechemistry.chemical_compoundEndocrinologyatherosclerosipreventionRisk FactorsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansParticle SizeRisk factorNational Cholesterol Education ProgramTriglycerideVascular diseasebusiness.industrydense LDLsmallAtherosclerosismedicine.diseaseLipoproteins LDLEndocrinologyDiabetes Mellitus Type 2chemistrydiabeteCardiologylipids (amino acids peptides and proteins)Metabolic syndromebusiness
researchProduct

Vitamin D status and hypercholesterolemia in Spanish general population.

2013

Low serum 25-hydroxyvitamin D [25(OH)D] levels have been associated with increased prevalence of cardiovascular diseases. A possible relation between lipids and 25(OH)D might explain this association. This investigation aimed to determine the association between vitamin D and cholesterol, as well as the influence of statins on this association. This was a cross-sectional population-based study with 177 subjects aged 18-84 years. We collected demographics and data on sun exposure, sun protection habits, current medication including lipid-lowering drugs, and estimated vitamin D intake. Serum measurements included levels of 25(OH)D, parathyroid hormone (PTH), calcium, phosphorus, total cholest…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationchemistry.chemical_elementParathyroid hormonevitamin DDermatologyCalciumstatinsFasting glucoselipidschemistry.chemical_compoundInternal medicineReportVitamin D and neurologyMedicineeducationLdl cholesteroleducation.field_of_studyCholesterolbusiness.industrycholesterol25-hydroxyvitamin DEndocrinologychemistryLDL cholesterollipids (amino acids peptides and proteins)businessLipoproteinDermato-endocrinology
researchProduct

The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis

2008

Small, dense low density lipoproteins (LDL) are associated with increased risk for cardiovascular disease and seem to be an important predictor of cardiovascular events and progression of coronary artery disease. In addition, the predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III). Less data is available on the role of LDL size in the prevention of vascular diseases, including peripheral arterial disease, carotid artery disease and abdominal aortic aneurysm. The NCEP-ATP III stated that clinical non-coronary atherosclerosis carries a risk for coronary heart disease …

medicine.medical_specialtyEndocrinologybusiness.industryEpidemiologyInternal medicineLow densitymedicineSmall dense LDL coronary heart disease atherosclerosis prevention peripheral arterial disease carotid artery disease abdominal aortic aneurysmbusinessCardiology and Cardiovascular MedicineVascular Disease Prevention
researchProduct